論文・総説 - 末永　光邦

1. Morikawa R, Nitta K, Yasuda S, Kano Y, Noji R, Aoyama S, Sato S, Ikeda S, Okamoto R, Nagata M, Mori T, Suenaga M. Identification of risk factors for gastrointestinal immune-related adverse events associated with immune check point inhibitors. Expert opinion on drug safety. 2024.12; ( PubMed, DOI )

2. Suenaga M, Mashima T, Kawata N, Dan S, Seimiya H, Yamaguchi K. Exploratory Study Identifies Matrix Metalloproteinase-14 and -9 as Potential Biomarkers of Regorafenib Efficacy in Metastatic Colorectal Cancer. Cancers. 2024.08; 16 (16): ( PubMed, DOI )

3. Suenaga M, Yamauchi S, Morikawa R, Noji R, Kano Y, Tokunaga M, Kinugasa Y. Chemotherapy and COVID-19 Vaccination in Patients With Gastrointestinal Cancer. In vivo (Athens, Greece). 2024.05; 38 (3): 1278-1284. ( PubMed, DOI )

4. Naito T, Noji R, Kugimoto T, Kuroshima T, Tomioka H, Fujiwara S, Suenaga M, Harada H, Kano Y. The Efficacy of Immunotherapy and Clinical Utility of Comprehensive Genomic Profiling in Adenoid Cystic Carcinoma of Head and Neck. Medicina (Kaunas, Lithuania). 2023.12; 59 (12): ( PubMed, DOI )

5. Yuriko Matsumiya, Mitsukuni Suenaga, Toshiaki Ishikawa, Toshifumi Kudo, Tsuyoshi Nakagawa, Kentaro Okamoto, Masanori Tokunaga, Claudia Hurtado, Yuki Yamada, Kentaro Oka, Motomichi Takahashi, Luis Francisco Lopez Kostner, Miguel Luis O'Ryan Gallardo, Hiroyuki Uetake, Yusuke Kinugasa. Clinical significance of Bacteroides fragilis as a potential prognostic factor in colorectal cancer Anaerobe. 2023.10; ( DOI )

6. Kano Y, Suenaga M, Uetake H. Strategic Insight into the Combination Therapies for Metastatic Colorectal Cancer. Current oncology (Toronto, Ont.). 2023.07; 30 (7): 6546-6558. ( PubMed, DOI )

7. Noji R, Tohyama K, Kugimoto T, Kuroshima T, Hirai H, Tomioka H, Michi Y, Tasaki A, Ohno K, Ariizumi Y, Onishi I, Suenaga M, Mori T, Okamoto R, Yoshimura R, Miura M, Asakage T, Miyake S, Ikeda S, Harada H, Kano Y. Comprehensive Genomic Profiling Reveals Clinical Associations in Response to Immune Therapy in Head and Neck Cancer. Cancers. 2022.07; 14 (14): ( PubMed, DOI )

8. Kumaki Y, Olsen S, Suenaga M, Nakagawa T, Uetake H, Ikeda S. Comprehensive Genomic Profiling of Circulating Cell-Free DNA Distinguishes Focal <i>MET</i> Amplification from Aneuploidy in Diverse Advanced Cancers. Current oncology (Toronto, Ont.). 2021.09; 28 (5): 3717-3728. ( PubMed, DOI )

9. Mitsukuni Suenaga, W U Zhang, Tetsuo Mashima, Marta Schirripa, Shu Cao, Satoshi Okazaki, Martin D Berger, Yuji Miyamoto, Afsaneh Barzi, Toshiharu Yamaguchi, Heinz-Josef Lenz. Potential Molecular Cross Talk Among CCR5 Pathway Predicts Regorafenib Responsiveness in Metastatic Colorectal Cancer Patients. Cancer Genomics Proteomics. 2021.04; 18 (3): 317-324. ( PubMed, DOI )

10. Mitsukuni Suenaga, Marta Schirripa, Shu Cao, Wu Zhang, Chiara Cremolini, Sara Lonardi, Satoshi Okazaki, Martin D Berger, Yuji Miyamoto, Shivani Soni, Afsaneh Barzi, Toshiharu Yamaguchi, Fotios Loupakis, Alfredo Falcone, Heinz-Josef Lenz. Clinical significance of enterocyte-specific gene polymorphisms as candidate markers of oxaliplatin-based treatment for metastatic colorectal cancer. Pharmacogenomics J. 2021.02; ( PubMed, DOI )

11. Kazuo Kobayashi, Erika Sugiyama, Eiji Shinozaki, Takeru Wakatsuki, Masataka Tajima, Hiyori Kidokoro, Takeshi Aoyama, Yasuhiro Nakano, Kazuyoshi Kawakami, Koki Hashimoto, Mitsukuni Suenaga, Takashi Ichimura, Mariko Ogura, Keisho Chin, Izuma Nakayama, Akira Ooki, Daisuke Takahari, Wataru Suzuki, Takashi Yokokawa, Yuichi Minowa, Tomoko Hiraoka, Kenichi Suzuki, Hitoshi Sato, Toshihiro Hama, Kensei Yamaguchi. Associations among plasma concentrations of regorafenib and its metabolites, adverse events, and ABCG2 polymorphisms in patients with metastatic colorectal cancers. Cancer Chemother Pharmacol. 2021.02; ( PubMed, DOI )

12. Takahari Daisuke, Shinozaki Eiji, Wakatsuki Takeru, Ooki Akira, Ozaka Masato, Suzuki Takeshi, Nakayama Izuma, Osumi Hiroki, Kamiimabeppu Daisaku, Sato Taro, Ogura Mariko, Suenaga Mitsukuni, Chin Keisho, Yamaguchi Kensei. Managing a gastrointestinal oncology practice in Japan during the COVID-19 pandemic: single institutional experience in The Cancer Institute Hospital of Japanese Foundation for Cancer Research(和訳中) International Journal of Clinical Oncology. 2021.02; 26 (2): 335-344. ( 医中誌 )

13. Suenaga M, Cao S, Zhang W, Matsusaka S, Okazaki S, Berger MD, Miyamoto Y, Schirripa M, Barzi A, Yamamoto N, Yamaguchi T, Lenz HJ. Role of enterocyte-specific gene polymorphisms in response to adjuvant treatment for stage III colorectal cancer. Pharmacogenetics and genomics. 2021.01; 31 (1): 10-16. ( PubMed, DOI )

14. Takahari Daisuke, Shinozaki Eiji, Wakatsuki Takeru, Ooki Akira, Ozaka Masato, Suzuki Takeshi, Nakayama Izuma, Osumi Hiroki, Kamiimabeppu Daisaku, Sato Taro, Ogura Mariko, Suenaga Mitsukuni, Chin Keisho, Yamaguchi Kensei. Managing a gastrointestinal oncology practice in Japan during the COVID-19 pandemic: single institutional experience in The Cancer Institute Hospital of Japanese Foundation for Cancer Research INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY. 2020.10; ( PubMed, DOI )

15. Mitsukuni Suenaga, Tetsuo Mashima, Naomi Kawata, Takeru Wakatsuki, Shingo Dan, Hiroyuki Seimiya, Kensei Yamaguchi. Serum IL-8 level as a candidate prognostic marker of response to anti-angiogenic therapy for metastatic colorectal cancer. Int J Colorectal Dis. 2020.09; ( PubMed, DOI )

16. Mitsukuni Suenaga, Marta Schirripa, Shu Cao, Wu Zhang, Dongyun Yang, Chiara Cremolini, Sabina Murgioni, Sara Lonardi, Yan Ning, Satoshi Okazaki, Martin D Berger, Yuji Miyamoto, Afsaneh Barzi, Fotios Loupakis, Alfredo Falcone, Heinz-Josef Lenz. Single Nucleotide Polymorphisms in MiRNA Binding Sites of Nucleotide Excision Repair-Related Genes Predict Clinical Benefit of Oxaliplatin in FOLFOXIRI Plus Bevacizumab: Analysis of the TRIBE Trial. Cancers (Basel). 2020.06; 12 (7): ( PubMed, DOI )

17. Berger Martin D., Ning Yan, Stintzing Sebastian, Heinemann Volker, Cao Shu, Zhang Wu, Yang Dongyun, Miyamoto Yuji, Suenaga Mitsukuni, Schirripa Marta, Hanna Diana L., Soni Shivani, Puccini Alberto, Tokunaga Ryuma, Naseem Madiha, Battaglin Francesca, Cremolini Chiara, Falcone Alfredo, Loupakis Fotios, Lenz Heinz-Josef. A polymorphism within the R-spondin 2 gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab: data from FIRE-3 and TRIBE trials EUROPEAN JOURNAL OF CANCER. 2020.05; 131 89-97. ( PubMed, DOI )

18. Kitagawa Yusuke, Osumi Hiroki, Shinozaki Eiji, Ota Yumiko, Nakayama Izuma, Suzuki Takeshi, Wakatsuki Takeru, Ogura Mariko, Ooki Akira, Takahari Daisuke, Suenaga Mitsukuni, Chin Keisho, Yamaguchi Kensei. Clinical utility of polyethylene glycol conjugated granulocyte colony-stimulating factor (PEG-G-CSF) for preventing severe neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI plus bevacizumab: a single-center retrospective study BMC CANCER. 2020.04; 20 (1): 358. ( PubMed, DOI )

19. Nakayama Izuma, Takahari Daisuke, Wakatsuki Takeru, Osumi Hiroki, Chin Keisho, Ogura Mariko, Sato Taro, Suzuki Takeshi, Kamiimabeppu Daisaku, Ooki Akira, Suenaga Mitsukuni, Shinozaki Eiji, Yamaguchi Kensei. Single-institute comparison of the efficacy of systemic chemotherapy for oesophagogastric junction adenocarcinoma and stomach adenocarscinoma in a metastatic setting ESMO OPEN. 2020.03; 5 (2): ( PubMed, DOI )

20. Suenaga Mitsukuni, Wakatsuki Takeru, Mashima Tetsuo, Ogura Mariko, Ichimura Takashi, Shinozaki Eiji, Nakayama Izuma, Osumi Hiroki, Ota Yumiko, Takahari Daisuke, Chin Keisho, Seimiya Hiroyuki, Yamaguchi Kensei. A phase I study to determine the maximum tolerated dose of trifluridine/tipiracil and oxaliplatin in patients with refractory metastatic colorectal cancer: LUPIN study INVESTIGATIONAL NEW DRUGS. 2020.02; 38 (1): 111-119. ( PubMed, DOI )